ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0550

Clinical and Genetic Factors Associated with Anti-TNF Therapy Initiation in Radiographic Axial Spondyloarthritis: A 15-Year Observational Study

Tae-jong Kim1, Bora Nam2, So-Young Bang3, Youngho Park4, Ji Hui Shin5, Sungsin Jo6 and Tae-Hwan Kim7, 1Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwang-Ju, South Korea, 2Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3Hanyang University, Seoul, Republic of Korea, 4Department of Big Data Application College of Smart Convergence, Hannam University, Daejeon, Republic of Korea, 5Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 6Department of Biology, Soonchunhyang University, Asan,, Republic of Korea, 7Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

Meeting: ACR Convergence 2025

Keywords: spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: To identify clinical and genetic factors associated with the initiation of anti-TNF (tumor necrosis factor) therapy in patients with radiographic axial spondyloarthritis (r-axSpA) who respond poorly to NSAIDs (non-steroidal anti-inflammatory drugs).

Methods: A total of 445 Korean r-axSpA patients were enrolled and analyzed through genome-wide association studies (Table 1). The observation period started at the initial visit and continued until the initiation of anti-TNF therapy or the last follow-up, spanning 15 years. Multiple linear regression was utilized to identify clinical and genetic predictors of initiating anti-TNF therapy. Pathway analysis was also conducted.

Results: During 3658.8 person-years of observation, 277 patients initiated anti-TNF therapy. Clinical factors significantly associated with the initiation of anti-TNF therapy included younger age at symptom onset (β = -0.008, p = 3.91×10⁻⁵), presence of peripheral arthritis (β = 0.181, p = 1.39×10⁻⁷), and higher all-time averaged CRP levels (β = 0.022, p = 0.009). Additionally, several functional SNPs were nominally associated with anti-TNF therapy initiation. These included a synonymous variant in SNAP47 (rs117950953, p = 3.69×10⁻⁵), a missense variant in ANKRD24 (rs10413818, p = 8.47×10⁻⁵), and a variant in the 3′-UTR of CAV3 (rs7629329, p = 8.31×10⁻⁵), after adjusting for significant clinical factors (Table 2). Pathway analysis identified a significant association with the cell adhesion pathway (p = 7.96×10⁻⁵, Bonferroni-corrected p = 5.88×10⁻³).

Conclusion: This study highlights significant clinical and genetic factors associated with the initiation of anti-TNF therapy in r-axSpA patients with inadequate responses to NSAIDs, offering potential predictors for clinical application.

Supporting image 1Table 1.

Supporting image 2Table 2.


Disclosures: T. Kim: None; B. Nam: None; S. Bang: None; Y. Park: None; J. Shin: None; S. Jo: None; T. Kim: Samsung Bioepis, 5.

To cite this abstract in AMA style:

Kim T, Nam B, Bang S, Park Y, Shin J, Jo S, Kim T. Clinical and Genetic Factors Associated with Anti-TNF Therapy Initiation in Radiographic Axial Spondyloarthritis: A 15-Year Observational Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/clinical-and-genetic-factors-associated-with-anti-tnf-therapy-initiation-in-radiographic-axial-spondyloarthritis-a-15-year-observational-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-and-genetic-factors-associated-with-anti-tnf-therapy-initiation-in-radiographic-axial-spondyloarthritis-a-15-year-observational-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology